Homologous Recombination Deficiency (HRD) testing helps personalize treatment for ovarian cancer by identifying tumors with impaired DNA repair mechanisms. Patients with HRD-positive tumors, including those with BRCA1/2 mutations, may benefit from targeted therapies like PARP inhibitors. This test enables oncologists to tailor treatment plans, improve outcomes, and avoid unnecessary side effects.
30 days upon receipt of sample in the lab.
Service will be provided at your given address. Home service is available in the following areas: Quezon City, San Juan City, Mandaluyong City, Manila City, Caloocan City, Pasig City, and Marikina City only.
Note: Price is exclusive of the home service fee. The total amount will be calculated at checkout.